Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|November 16, 2020
Molecular Profiling-Based Precision Medicine in Cancer: A Review of Current Evidence and ChallengesQi Zhang, Qihan Fu, Xueli Bai, et al.
Frontiers in Oncology|March 20, 2023
Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burdenMengyao Dai, Jianpeng Sheng, Qi Zhang, et al.
Saudi Journal of Biological Sciences|August 16, 2018
Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 predicts poor prognosis in hepatocellular carcinomaWanyuan Chen, Qihan Fu, Francia Fang, et al.
Journal of Neuroengineering and Rehabilitation|March 21, 2025
Wearable fall risk assessment by discriminating recessive weak foot individualZhen Song, Jianlin Ou, Shibin Wu, et al.
Biomaterials|July 27, 2016
A redox-sensitive, oligopeptide-guided, self-assembling, and efficiency-enhanced (ROSE) system for functional delivery of microRNA therapeutics for treatment of hepatocellular carcinomaQida Hu, Kai Wang, Xu Sun, et al.
Human Vaccines & Immunotherapeutics|June 29, 2021
CAR-based cell therapy: evaluation with bibliometrics and patent analysisYajun Yuan, Qihan Fu, Yaqun Zhang, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|February 1, 2020
Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysisMao Ye, Qi Zhang, Yiwen Chen, et al.
International Journal of Surgery (London, England)|November 10, 2016
Meta-analysis of invagination and duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: An updateXu Sun, Qi Zhang, JingYing Zhang, et al.
Molecular Cancer|July 15, 2017
Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancerQi Zhang, Yu Lou, Jingying Zhang, et al.
Gastroenterology Report|February 8, 2023
Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II studyHangyu Zhang, Zhou Tong, Lulu Liu, et al.
Pageof 4